Please login to the form below

Not currently logged in
Email:
Password:

EC consults on orphan drug application guidelines

Also seeks input on the transfer of designations from one sponsor to another

The European Commission (EC) has put its proposed guideline on the format and content of applications for orphan drug status out to public consultation.

The proposed guideline provides supplementary advice on how to compile the documents that should be provided by sponsors in an application for orphan medicinal product designation

It also covers the provision of advice to sponsors wishing to transfer the designation of an orphan medicinal product and/or to change the name or address of a sponsor.

• Comments and suggestions are invited by September, 30 and should emailed to: sanco-pharmaceuticals-d5@ec.europa.eu

19th July 2013

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Origins Insights

Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...